Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 4 1Phase 2/3 1

Status

Unknown 4Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 69Gastrointestinal 39Breast 20Gynecologic 13Sarcoma 12Head & Neck 10CNS 8Endocrine 6Genitourinary 5Tumor-Agnostic 4Other solid neoplasm 3NET 2Dermatologic 2

Conditions

Pheochromocytoma 4Paraganglioma 3Paraganglioma, Extra-Adrenal 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Gastroenteropancreatic Neuroendocrine Tumor G3 1Digestive System Neoplasms 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × anlotinib × Endocrine × Clear all
NCT06429397 2025-04-29

Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma

Sun Yat-sen University

Phase 2 Not yet recruiting
22 enrolled
Endocrine

Pheochromocytoma

NCT04860700 2024-06-12

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Peking Union Medical College Hospital

Phase 2 Completed
27 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05883085 2023-05-31

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Peking Union Medical College Hospital

Phase 2 Unknown
10 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05133349 2021-11-24

EASOAIPPGL

Nanjing First Hospital, Nanjing Medical University

Phase 2 Unknown
20 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
150 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

NCT03457844 2018-09-11

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumor G3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡